Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680167 | 0.89 | MAPT (0.57) | HTTLMNAMAPTESR1ESR2 | |
| Hydrochloric Acid SCHEMBL1600459 | 0.87 | MAPT (0.55) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL1898829 | 0.85 | LMNA (0.50) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL29904708 | 0.83 | SRD5A2 (0.62) | HTTLMNAMAPTSRD5A2L3MBTL1 | |
| SCHEMBL28563770 | 0.83 | SRD5A2 (0.62) | HTTLMNAMAPTSRD5A2L3MBTL1 | |
| Benzophenone SCHEMBL27781305 | 0.83 | PBRM1 (0.62) | LMNAMAPTHPGDSMN1; SMN2SRD5A2 | |
| SCHEMBL144914 | 0.83 | PBRM1 (0.62) | LMNAMAPTHPGDSMN1; SMN2SRD5A2 | |
| SCHEMBL30874183 | 0.83 | PBRM1 (0.62) | LMNAMAPTHPGDSMN1; SMN2SRD5A2 | |
| SCHEMBL12490393 | 0.82 | HTT (0.70) | HTTLMNAMAPTESR1ESR2 | |
| SCHEMBL30259798 | 0.82 | MAPT (0.47) | HTTLMNAMAPTESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875727-B2 | methyl [5(6)-(4-alanylaminophenylthio)-1H-benzimidazol-2yl]carbamate; for treating neovascularization, solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2011-01-25 | — | — | US | disclosed |
| EP-1140078-B1 | BENZIMIDAZOLE VASCULAR DAMAGING AGENTS | ANGIOGENE PHARM LTD (GB) | 2007-08-29 | — | — | EP | disclosed |
| US-20060264492-A1 | Benzimidazole vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. | 2006-11-23 | — | — | US | disclosed |
| US-7081469-B2 | Benzimidazole vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-07-25 | — | — | US | disclosed |
| US-20040058972-A1 | Benzimidazole vascular damaging agents | DAVIS PETER DAVID (GB) | 2004-03-25 | — | — | US | disclosed |
| US-6645950-B1 | Benzimidazole-2-carbamates; antitumor agents; angiogenesis inhibitors; macular degeneration, diabetic retinopathy, rheumatic arthritis, psoriasis, and atherosclerosis treatment | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2003-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058972-A1 | Benzimidazole vascular damaging agents | FLT1, FLT4, PCNA | HTT 4238/4885LMNA 1447/4885MAPT 2879/4885 |
| US-20060264492-A1 | Benzimidazole vascular damaging agents | FLT4, PCNA, FLT1 | HTT 4071/4885LMNA 1373/4885MAPT 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.